Application of the Novel Nalu™ Neurostimulation System for Peripheral Nerve Stimulation

Abstract

Peripheral nerve stimulation is an established treatment modality for chronic neuropathic pain. Over the last decade, with the advent of innovative devices and delivery platforms, peripheral nerve stimulation has evolved from invasive open surgeries to image-guided, minimally invasive percutaneous procedures. The authors hereby present a novel device, the Nalu™ Neurostimulation System (Nalu Medical, CA, USA), which has established its advantages in providing predictable and reliable peripheral nerve stimulation therapy for chronic neuropathic pain management. This novel device is effective in treating chronic pain conditions such as post-herniorrhaphy pain syndrome, intercostal neuralgia, post-laminectomy syndrome, and complex regional pain syndrome and holds great promise for the treatment of peripheral neuropathic pain.

Plain language summary

Chronic nerve pain is a debilitating condition that can affect quality of life and functioning. The Nalu™ Neurostimulation System (Nalu Medical, CA, USA) provides long-term pain relief without medications. There are numerous devices currently available that can be utilized to block pain signals using small wires. This system is unique because the wires placed over affected nerves are powered by an external battery that does not require permanent surgical implantation. Pain after hernia surgery, back surgery, hip surgery and knee surgery, as well as nerve pain can be effectively managed by this system.

Keywords::

• chronic pain
• micro-IPG
• miniaturized neuromodulation
• neuromodulation
• neuropathic pain
• novel
• peripheral nerve stimulation
• peripheral neuralgia

Author contributions

All authors contributed to study conception, design, administration and reporting as well as the analysis and interpretation of data.

Financial&competing interests disclosure

H Kalia is a consultant for Abbott and Omnia Medical. S Pritzlaff is a consultant for SPR Therapeutics, EBT Medical and Nalu Medical. E Ottestad is a consultant for SPR Therapeutics, Nalu Medical, Coloplast, Invicta Medical and Reflex Medical. A Gulati is a consultant for Medtronic, Flowonix, SPR Therapeutics, Nalu Medical and Tremeau Pharmaceuticals and an adviser for AIS Healthcare and Spark Biomedical. J Makous is a paid consultant for and shareholder of Nalu Medical. K Chakravarthy is a consultant for Medtronic, Biotronik, Mainstay Medical, SI-BONE, Bioness, PainTEQ, Vivex Biologics and Vertos Medical. He also has stock options in Nalu Medical, Mainstay Medical, Higgs Boson Health, UMEHEAL, Oska Wellness, Aya Biosciences, Rune Labs and Yantra Biomed. In addition, he is a founder of Newrom Biomedical, AccuFix Medical and Douleur Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.